Traws Pharma Q3 net loss $8.5M; cash $5.4M; Phase 2 starts for COVID and flu drugs in 2025

Traws Pharma, Inc.

2024-Q3 EPS reported -$130.87 vs consensus -$6.25 ▼ miss (-1994.8%)

Net loss of $8.5M ($8.81 per share) vs $4.7M loss in Q3 2023; R&D expense $5.1M, G&A $3.5M.
Cash and short-term investments $5.4M as of Sept 30, down from $20.8M at Dec 31, 2023.
Ratutrelvir (COVID) Phase 1 data supports once-daily dosing without ritonavir; Phase 2 targeted in 2025.
Tivoxavir marboxil (flu) Phase 1 data supports single-dose treatment; Phase 2 targeted in 2025.
Luba Greenwood appointed to board of directors; shares outstanding 3,025,554 after 25:1 reverse split.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.